(CercleFinance.com) – Goldman Sachs has gone short on the stock due to uncertainties surrounding the launch of Viaskin Peanut.
Goldman Sachs analysts, who have so far been at ‘neutral’ and whose price target remains at two euros, believe that Viaskin Peanut is in a position to take market share in the treatment of peanut allergy in despite the lead taken by its rival drug, Palforzia developed by Nestlé and Aimmune.
But the design office says it is worried about the product’s marketing schedule, which has already been faced with multiple postponements.
The latest setback, he recalls, dates back to last September, when the phase 3 clinical study was suspended pending additional data on the patch.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
